Abstract
Objective: The phase 3 VELIA trial demonstrated that veliparib dosed concurrently with carboplatin and paclitaxel and continued as maintenance monotherapy resulted in significantly better progression-free survival (PFS) compared to carboplatin and paclitaxel alone in patients with newly diagnosed advanced high-grade serous ovarian carcinoma (HGSC). VELIA enrolled patients without regard to germline or somatic BRCA mutations (BRCAm), homologous recombination deficiency (HRD), or platinum sensitivity, providing a unique opportunity to evaluate the prognostic and predictive role of the HRD assay.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
